NM_000268.4(NF2):c.1735A>C (p.Lys579Gln) AND Neurofibromatosis, type 2

Clinical significance:Uncertain significance (Last evaluated: May 27, 2020)

Review status:1 star out of maximum of 4 stars

criteria provided, single submitter

Based on:
1 submission [Details]
Record status:

Allele description [Variation Report for NM_000268.4(NF2):c.1735A>C (p.Lys579Gln)]

NM_000268.4(NF2):c.1735A>C (p.Lys579Gln)

NF2:NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
Genomic location:
Preferred name:
NM_000268.4(NF2):c.1735A>C (p.Lys579Gln)
  • NC_000022.11:g.29681599A>C
  • NG_009057.1:g.83044A>C
  • NM_000268.4:c.1735A>CMANE SELECT
  • NM_016418.5:c.1735A>C
  • NM_181825.3:c.1735A>C
  • NM_181828.3:c.1609A>C
  • NM_181829.3:c.1612A>C
  • NM_181830.3:c.1486A>C
  • NM_181831.3:c.1486A>C
  • NM_181832.3:c.1735A>C
  • NM_181833.3:c.448-13153A>C
  • NP_000259.1:p.Lys579Gln
  • NP_057502.2:p.Lys579Gln
  • NP_861546.1:p.Lys579Gln
  • NP_861966.1:p.Lys537Gln
  • NP_861967.1:p.Lys538Gln
  • NP_861968.1:p.Lys496Gln
  • NP_861969.1:p.Lys496Gln
  • NP_861970.1:p.Lys579Gln
  • LRG_511t2:c.1735A>C
  • LRG_511:g.83044A>C
  • LRG_511p2:p.Lys579Gln
  • NC_000022.10:g.30077588A>C
  • NR_156186.2:n.2217A>C
Protein change:
dbSNP: rs2067138432
NCBI 1000 Genomes Browser:
Molecular consequence:
  • NM_181833.3:c.448-13153A>C - intron variant - [Sequence Ontology: SO:0001627]
  • NM_000268.4:c.1735A>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_016418.5:c.1735A>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_181825.3:c.1735A>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_181828.3:c.1609A>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_181829.3:c.1612A>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_181830.3:c.1486A>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_181831.3:c.1486A>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_181832.3:c.1735A>C - missense variant - [Sequence Ontology: SO:0001583]
  • NR_156186.2:n.2217A>C - non-coding transcript variant - [Sequence Ontology: SO:0001619]


Neurofibromatosis, type 2 (NF2)
NF 2; Neurofibromatosis central type; Acoustic schwannomas bilateral; See all synonyms [MedGen]
MONDO: MONDO:0007039; MedGen: C0027832; Orphanet: 637; OMIM: 101000

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
SCV001486649Invitaecriteria provided, single submitter
Uncertain significance
(May 27, 2020)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing



Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240-242.

PubMed [citation]

Details of each submission

From Invitae, SCV001486649.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)


This sequence change replaces lysine with glutamine at codon 579 of the NF2 protein (p.Lys579Gln). The lysine residue is moderately conserved and there is a small physicochemical difference between lysine and glutamine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with NF2-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Nov 27, 2021

Support Center